Evidence map›Paper›PMID 28881734›Full record

ArticleOncotarget2017

Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor.

Jeewon Kim, June Ho Shin, Che-Hong Chen, Leslie Cruz, Lovisa Farnebo, Jieying Yang, Paula Borges, Gugene Kang, Daria Mochly-Rosen, John B Sunwoo

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. ALDH Inhibition-Primed Photocatalysis Disrupts Cancer Stemness Plasticity.Angewandte Chemie (International ed. in English) · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Article
  17. Review
  18. Article
  19. HPVTranslational oncology · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Jeewon KimStanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
June Ho ShinStanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Che-Hong ChenDepartment of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, 94305, USA.
Leslie CruzDepartment of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, 94305, USA.
Lovisa FarneboDivision of Head and Neck Surgery, Department of Otolaryngology, Stanford University, Stanford, CA, 94305, USA.
Jieying YangStanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Paula BorgesDivision of Head and Neck Surgery, Department of Otolaryngology, Stanford University, Stanford, CA, 94305, USA.
Gugene KangDepartment of Developmental Biology, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Daria Mochly-RosenDepartment of Chemical and Systems Biology, Stanford University, School of Medicine, Stanford, CA, 94305, USA.
John B SunwooStanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA, 94305, USA.
Stanford University · US

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4M
TUMOR BIOLOGYT32CA009151 · NCI · STANFORD UNIVERSITY · PI CLEARY, MICHAEL L · 1985 to 2014
$5.5M
Mechanisms of Ethanol-Induced Cardiac ProtectionR37AA011147 · NIAAA · STANFORD UNIVERSITY · PI MOCHLY-ROSEN, DARIA · 2009 to 2018
$5.3M
Characterization and Targeting of CD271 in Oral Cancer-Initiating CellsR56DE024402 · NIDCR · STANFORD UNIVERSITY · PI SUNWOO, JOHN B · 2014 to 2014
$436k
NCI NIH HHS P30 CA124435NCI NIH HHS T32 CA009151NIAAA NIH HHS R37 AA011147NIDCR NIH HHS R56 DE024402
6 · The paper itself

Abstract

Chemoresistant cancer cells express high levels of aldehyde dehydrogenases (ALDHs), particularly in head and neck squamous cell carcinoma (HNSCC). The ALDH family of enzymes detoxify both exogenous and endogenous aldehydes. Since many chemotherapeutic agents, such as cisplatin, result in the generation of cytotoxic aldehydes and oxidative stress, we hypothesized that cells expressing high levels of ALDH may be more chemoresistant due to their increased detoxifying capacity and that inhibitors of ALDHs may sensitize them to these drugs. Here, we show that overall ALDH activity is increased with cisplatin treatment of HNSCC and that ALDH3A1 protein expression is particularly enriched in cells treated with cisplatin. Activation of ALDH3A1 by a small molecule activator (Alda-89) increased survival of HNSCC cells treated with cisplatin. Conversely, treatment with a novel small molecule ALDH inhibitor (Aldi-6) resulted in a marked decrease in cell viability, and the combination of Aldi-6 and cisplatin resulted in a more pronounced reduction of cell viability and a greater reduction in tumor burden

Indexed as

aldehyde dehydrogenasechemoresistancehead and neck squamous cell carcinomasmall molecule inhibitors

Identifiers

PMID28881734
PMCPMC5581033
OpenAlexW2606784762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.